Key clinical point: In low-weight and elderly acute coronary syndrome patients, low-dose prasugrel appears preferable to ticagrelor.
Major finding: Both the risk of ischemic events (hazard ratio, 0.82) and bleeding (HR, 0.72) events were numerically lower on low-dose prasugrel than ticagrelor.
Data Source: Prespecified substudy of the phase 4 randomized ISAR-REACT 5 trial.
Disclosures: The senior author, Dr. Kastrati, reported no potential conflicts of interest relevant to this study.
Menichelli M et al. Ann Intern Med. 2020 Jul 21. doi: 10.7326/M20-1806.